<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230714058777N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-02</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Iranian cumin extract (Bunium persicum) on infantile colic</public_title>
      <acronym></acronym>
      <scientific_title>Examination of the effect of Iranian cumin extract (Bunium persicum) on infantile colic: A randomized double-blind trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71549</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The researcher assigns a number to each patient using the random allocation rule method and then puts the cards on which the patient's number is written in an envelope in a random order. In this method, according to the sample volume, two sets of card with different colors with the same number equal to the total volume of the sample are put inside the envelope, then the eligible people entered into the study are randomly assigned to a color coded card from the envelope. According to the researcher's definition, if the red card is taken, they will enter the intervention group, and if the blue card is taken, they will enter the control group, Blinding description: In our method of blinding, the patient's companion, who is usually one of the parents, is unaware of the type of drug used. Also, the person collecting the information is unaware of the type of drug received by the patient. Placebo has the same color and smell as Bunium extract. The extract will be provided by Barij  Company in the same form and packaging in a coded form, under the supervision of a pharmacology expert.</study_design>
      <phase>3</phase>
      <hc_freetext>Infantile colic.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:in addition to relaxation techniques, the intervention group will receive 0.5 mL of oral extract of Bunium persicum 4 times a day in the form of oral drops (provided by Barij  Company) for two weeks. Intervention 2: Control group:The control group will not be deprived of the standard treatment, which is relaxation techniques. Relaxation techniques includeing making soothing sounds or singing songs, using slow and rhythmic shaking movements, walking, and using mild vibration-like movements such as the movements of cars are taught to parents at the beginning of the study.In addition, the control group will receive placebo in the form of drops with the same color and smell as cumin extract.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Checklists completed by mothers include individual data that can be published after de-identification

When:
The start of the period of access to data and documentation files will be 6 months after the results are published

To whom:
The data obtained from the study will be accessible to researchers working in academic and scientific centers as well as people working in the pharmaceutical industry.

Conditions:
The data obtained from the study can be used in order to help make the right medicine to control infant colic.

Where to obtain:
Contact the scientific officer of the project via email at talakesh.h@skums.ac.ir

How to obtain:
After correspondence with the scientific officer of the project through the e-mail address talakesh.h@skums.ac.ir, within two weeks after checking the purpose of data access, their request will be answered.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amin Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Parastar st.</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8816854633</zip>
        <telephone>009838132252416</telephone>
        <email>st-amini.a@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Talakesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Parastar st.</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88168854633</zip>
        <telephone>+98 38 3225 2416</telephone>
        <email>talakesh.h@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Infantile colic based on wessel`s criteria (paroxysms of crying episodes; lasting for more than 3h in a day; occuring three or more days per week for at least three weeks) diagnosed by pediatrician
age: 3-13 weeks
Gastational age: more than 37 weeks at birth
weight: more than 2500 gr at birth
Absence of underlying diseases or congenital disorders
No antibiotic use in the last two weeks</inclusion_criteria>
      <agemin>21 days</agemin>
      <agemax>91 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>failure to thrive
Recent use of antibiotics
age less than 3 weeks and more than 13 weeks
low birth weight
prematurity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R10.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other and unspecified abdominal pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:in addition to relaxation techniques, the intervention group will receive 0.5 mL of oral extract of Bunium persicum 4 times a day in the form of oral drops (provided by Barij  Company) for two weeks.</i_keyword>
      <i_keyword>Control group:The control group will not be deprived of the standard treatment, which is relaxation techniques. Relaxation techniques includeing making soothing sounds or singing songs, using slow and rhythmic shaking movements, walking, and using mild vibration-like movements such as the movements of cars are taught to parents at the beginning of the study.In addition, the control group will receive placebo in the form of drops with the same color and smell as cumin extract.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The average duration of crying in infant. Timepoint: the beginning of the study and 7, 14, 21 and 28 days after the start of the study. Method of measurement: check list.</prim_outcome>
      <prim_outcome>The number of times the infant cries. Timepoint: the beginning of the study and 7, 14, 21 and 28 days after the start of the study. Method of measurement: checklist.</prim_outcome>
      <prim_outcome>Duration of sleep. Timepoint: the beginning of the study and 7, 14, 21 and 28 days after the start of the study. Method of measurement: check list.</prim_outcome>
      <prim_outcome>Number of defications. Timepoint: the beginning of the study and 7, 14, 21 and 28 days after the start of the study. Method of measurement: chrcklist.</prim_outcome>
      <prim_outcome>Age. Timepoint: the beginning of the study. Method of measurement: the history.</prim_outcome>
      <prim_outcome>Sex. Timepoint: the beginning of the study. Method of measurement: the history.</prim_outcome>
      <prim_outcome>Birth weight. Timepoint: the beginning of the study. Method of measurement: the history.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-31</approval_date>
        <contact_name>Ethics committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>Ayatollah Kashani St. Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
